Thiazolidinedione
Rosiglitazone
ROSIGLITAZONE
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.92 (-1.48 to -0.35) | 0.53 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.89 (-1.46 to -0.31) | 0.54 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.63 (0.32 to 4.88) | 0.12 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.81 (0.20 to 5.39) | 0.16 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.27 (0.32 to 4.51) | 0.53 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.16 (0.29 to 4.48) | 0.62 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.22 (0.28 to 5.48) | 0.41 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.18 (0.26 to 5.66) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.26 (0.05 to 0.95) | 0.91 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.28 (0.05 to 1.14) | 0.83 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.07 (0.00 to 0.70) | 0.96 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.07 (0.00 to 0.83) | 0.95 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.72 (0.11 to 3.77) | 0.74 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.77 (0.12 to 4.16) | 0.69 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.15 (0.00 to 2.25) | 0.88 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.15 (0.00 to 2.54) | 0.85 |